Incidência das coagulopatias na infecção por Covid-19 / Incidence of coagulopathies in Covid-19 infection
DOI:
https://doi.org/10.34119/bjhrv4n4-211Keywords:
COVID-19, Coagulopatias, Coagulação.Abstract
Uma crise mundial na saúde instalou-se com o advento do “novo coronavírus” (COVID-19), de alta disseminação, que compromete sobretudo o sistema respiratório e se relaciona a uma alta prevalência de coagulopatias que contribuem para elevação do risco de morte. Objetiva-se compreender a prevalência aumentada dos distúrbios da coagulação sanguínea nos pacientes com COVID-19. Foi realizada uma Revisão Integrativa da Literatura abordando a seguinte problemática: qual a prevalência de coagulopatias na infecção por coronavírus? E utilizados descritores em Ciências da Saúde (DeCs) em inglês “disseminated intravascular coagulation” e “covid-19” para pesquisa na Biblioteca Virtual em Saúde (BVS) e no U.S. National Library of Medicine and the National Institutes of Health (PUBMED). Dos 542 artigos encontrados que passaram pelo crivo dos critérios de inclusão e exclusão, 33 artigos foram utilizados nesta pesquisa. Pacientes com COVID-19, sobretudo os em estado crítico, mostraram um maior risco de desenvolver distúrbios tromboembólicos em virtude da exacerbação de processos inflamatórios, pela promoção do aumento da trombina e liberação maciça de citocinas e quimiocinas, além da presença do dímero D e com isso elevando o risco de morte. Nesse sentido, terapias tromboprofiláticas são apresentadas na tentativa de reduzir a taxa de óbitos em pacientes acometidos pela COVID-19. Portanto, o estudo realizado mostra a prevalência de coagulopatias na infecção por COVID-19 e os principais fatores que se alteram em pacientes portadores da doença. Contudo, mais estudos randomizados são necessários para a compreensão dos mecanismos fisiopatológicos envolvidos nessas coagulopatias com a finalidade de tratamentos mais seguros e efetivos.
References
AL-SAMKARI, H. et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, The Journal of the American Society of Hematology, v. 136, n. 4, p. 489-500, 2020.
ASAKURA, H.; OGAWA, H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. International Journal of Hematology, p. 1-13, 2020.
AVILA, J. et al. Thrombotic complications of COVID-19. The American Journal of Emergency Medicine, 2020.
BOCCIA, M. et al. COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Archives for Chest Disease, v. 90, n. 2, 2020.
BRAY, M. A. et al. Microvascular thrombosis: experimental and clinical implications. Translational Research, 2020.
CARRILLO-ESPER, R. et al. Alteraciones de la coagulación en la COVID-19. Cirugia y cirujanos, v. 88, n. 6, p. 787-793, 2020.
CASTRO, R. A.; FRISHMAN, W. H. Thrombotic complications of COVID-19 infection: a review. Cardiology in review, v. 29, n. 1, p. 43-47, 2021.
COMINO-TRINIDAD, O. et al. Coagulación intravascular diseminada como forma de presentación de la enfermedad por coronavirus-19. Caso clínico. Revista Espanola De Anestesiologia Y Reanimacion, v. 68, n. 1, p. 41-45, 2021.
COMINO-TRINIDAD, O. et al. Disseminated intravascular coagulation as a form of presentation of coronavirus-19 disease. Clinical case. Revista Española de Anestesiología y Reanimación (English Edition), v. 68, n. 1, p. 41-45, 2021.
CONNORS, J. M.; LEVY, J. H. COVID-19 and its implications for thrombosis and anticoagulation. Blood, The Journal of the American Society of Hematology, v. 135, n. 23, p. 2033-2040, 2020.
DO ESPÍRITO SANTO, D. A.; LEMOS, A. C. B.; MIRANDA, C. H. In vivo demonstration of microvascular thrombosis in severe COVID-19. Journal of Thrombosis and Thrombolysis, v. 50, n. 4, p. 790-794, 2020.
GÓMEZ-MESA, J. E. et al. Thrombosis and Coagulopathy in COVID-19. Current Problems In Cardiology, [S.L.], v. 46, n. 3, p. 100742, mar. 2021.
HARENBERG, J.; FAVALORO, E. COVID-19: progression of disease and intravascular coagulation–present status and future perspectives. Clinical Chemistry and Laboratory Medicine (CCLM), v. 1, n. ahead-of-print, 2020.
HELMS, J. et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive care medicine, v. 46, n. 6, p. 1089-1098, 2020.
IBA, T. et al. Coagulopathy of coronavirus disease 2019. Critical care medicine, 2020.
KATNENI, U. K. et al. Coagulopathy and thrombosis as a result of severe COVID-19 infection: a microvascular focus. Not Peer-Reviewed, 2020.
KOLLIAS, A. et al. Thromboembolic risk and anticoagulant therapy in COVID?19 patients: emerging evidence and call for action. British journal of haematology, v. 189, n. 5, p. 846-847, 2020.
LAMEIJER, J.R.C. et al. Severe arterial thromboembolism in patients with Covid-19. Journal of Critical Care, v. 60, p. 106-110, 2020.
LEVI, M.; THACHIL, J. Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy—Either, Neither, or Both. In: Seminars in thrombosis and hemostasis. Thieme Medical Publishers, 2020. p. 781-784.
LEVI, M. et al. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet. Haematology, v. 7, n. 6, p. e438, 2020.
MARIETTA, M.; COLUCCIO, V.; LUPPI, M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Internal and emergency medicine, p. 1-13, 2020.
MARTÍN?ROJAS, R. M. et al. COVID?19 coagulopathy: an in?depth analysis of the coagulation system. European Journal of Haematology, v. 105, n. 6, p. 741-750, 2020.
MIESBACH, W.; MAKRIS, M. COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clinical and Applied Thrombosis/Hemostasis, v. 26, p. 1076029620938149, 2020.
RIBEIRO O.M.P., et al. Modelos de prática profissional de enfermagem: revisão integrativa da literatura. Rev. Enf. Ref. 2016;4(10):125-133.
RIBES, A. et al. Thromboembolic events and Covid-19. Advances in Biological Regulation, v. 77, p. 100735, 2020.
RIVEROS, D. et al. Coagulopathy and COVID-19. Recommendations for a changing reality. Medicina, v. 80, n. 5, p. 505-511, 2020.
SHI, W.; LV, J.; LIN, L.. Coagulopathy in COVID-19: Focus on vascular thrombotic events. Journal of molecular and cellular cardiology, v. 146, p. 32-40, 2020.
SINGH, P.; SCHWARTZ, R. A. Disseminated intravascular coagulation: A devastating systemic disorder of special concern with COVID?19. Dermatologic therapy, p. e14053, 2020.
SOUZA A.M., PEGORARO R.F. O psicólogo na UTI neonatal: revisão integrativa de literatura. Sau. & Transf. Soc. 2017;8(1):117-128.
SRIVASTAVA, S. et al. COVID-19 infection and Thrombosis. Clinica Chimica Acta, v. 510, p. 344-346, 2020.
TAL, S. et al. Venous thromboembolism complicated with COVID-19: what do we know so far?. Acta haematologica, v. 143, n. 5, p. 417-424, 2020.
UAPRASERT, N. et al. Systemic Coagulopathy in Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. Clinical and Applied Thrombosis/Hemostasis, v. 27, p. 1076029620987629, 2021.
VINAYAGAM, S.; SATTU, K. SARS-CoV-2 and coagulation disorders in different organs. Life Sciences, p. 118431, 2020.
WARKENTIN, T. E.; KAATZ, S. COVID-19 versus HIT hypercoagulability. Thrombosis research, 2020.
YANG, X. et al. Focus on coronavirus disease 2019 associated coagulopathy. Chinese Medical Journal, v. 133, n. 18, p. 2239, 2020.
